Pharmasanta group - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | - | - | - | - | 111,026 | 75,150 | 57,600 | 12,600 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | -191,430 | -174,286 | -172,665 | -530,867 | -368,844 | 1,440,679 | 1,754,546 | -594,337 |
| Equity | -200,449 | -374,735 | -547,401 | -1,078,268 | -1,447,111 | -6,432 | 1,748,115 | 1,443,778 |
| Liabilities | 4,720,854 | 4,895,389 | 5,067,821 | 14,607,224 | 12,820,340 | 11,264,332 | 11,709,581 | 12,115,614 |
| Non-current assets | 4,520,388 | 4,520,388 | 4,520,388 | 13,423,930 | 11,022,262 | 10,918,240 | 13,396,779 | 13,392,758 |
| Current assets | 17 | 266 | 32 | 48,970 | 350,531 | 339,603 | 60,428 | 166,598 |
| Total assets | 4,520,405 | 4,520,654 | 4,520,420 | 13,472,900 | 11,372,793 | 11,257,843 | 13,457,207 | 13,559,356 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 33,083 | 17,092 | 8,546 |
| Social insurance contributions | - | - | - | - | - | 5,496 | - | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | - | - | - | - | -32.3% | -23.4% | -78.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -4.2% | -3.9% | -3.8% | -3.9% | -3.2% | 12.8% | 13.0% | -4.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | 100.4% | -41.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | - | - | -332.2% | 1917.1% | 3046.1% | -4717.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | 6.7 | 8.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | 22,581 | 19,187 | 25,600 | 6,300 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharmasanta group - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-08-19 | 2024-08-26 | 0.09 |
| 2024-07-24 | 2024-07-28 | 0.09 |
| 2024-05-16 | 2024-05-20 | 52.51 |
| 2023-11-16 | 2023-11-29 | 0.01 |
| 2023-10-17 | 2023-10-29 | 0.01 |
| 2023-09-18 | 2023-09-27 | 0.01 |
| 2023-07-18 | 2023-07-27 | 0.01 |
| 2023-06-16 | 2023-06-28 | 0.01 |
| 2023-05-16 | 2023-05-29 | 0.01 |
| 2023-05-02 | 2023-05-03 | 0.01 |
| 2023-04-26 | 2023-04-28 | 0.01 |
| 2023-02-17 | 2023-02-26 | 2.75 |
| 2022-12-16 | 2022-12-28 | 0.14 |
| 2022-11-21 | 2022-11-28 | 0.14 |
| 2022-11-17 | 2022-11-18 | 0.14 |
Pharmasanta group - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-02-14 | 2025-02-24 | 0.03 |
| 2025-01-30 | 2025-02-13 | 0.04 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharmasanta group, UAB (code 304689987) is a Private Limited Liability Company engaged in Activities of head offices. In 2025, the company generated €12.6K in revenue and posted a net loss of €594.3K, marking a sharp deterioration from the profitable 2023-2024 period. Revenue fell 78.1% year on year in 2025 and was down 83.2% versus 2023, showing a clear contraction in operating turnover. In 2024, revenue was €57.6K and net profit €1.75M, while in 2023 revenue was €75.2K and net profit €1.44M. The very high margins in 2023 and 2024 were driven by extremely low revenue levels. The balance sheet remained sizable in 2025, with total assets of €13.56M, equity of €1.44M and liabilities of €12.12M. Long-term assets accounted for most of the asset base at €13.39M. Key ratios for 2025 indicate weak performance and leverage pressure: ROE was -41.2%, ROA was -4.4%, debt-to-equity was 8.39, and equity represented 10.7% of assets. Revenue per employee was €6.3K.